Bioinformatics (Oxford, England) · 2026
Polypharmacological Target-Aware Molecule Generation.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Wu Kehan, Zhang Wei, Guo Han, Liu Renhe, Shi Yu, Jin Peiran, Liu Haiguang, Chen Enhong, Qin Tao, Liu Zequn, Xia Yingce
Аннотация
MOTIVATION: Designing compounds capable of modulating multiple target proteins simultaneously (i.e., polypharmacology) is critical for treating complex diseases like cancer and neurodegenerative disorders. However, AI-driven multi-target drug design remains severely hindered by the scarcity of multi-target 3D structural data and the inefficiency of traditional "generate-then-filter" pipelines. There is a pressing need for scalable methods that can satisfy diverse binding constraints across multiple proteins without relying on scarce structural priors.
RESULTS: To overcome these bottlenecks, we reformulate multi-target drug design as a sequence-based generation task and introduce PolyTamGen, an end-to-end autoregressive framework. We first curate a large-scale ligand-centric bioactivity dataset from ChEMBL and BindingDB, comprising 1.6 million unique ligands and 4.9 million bioactivity entries. PolyTamGen encodes target protein sets using ESM3, compresses these high-dimensional features into compact tokens via an attention module, and feeds them into a sequence-based compound generator to produce the final multi-target ligands. We further apply Direct Preference Optimization (DPO) to improve docking-based affinity proxies and drug-likeness. Extensive experiments on dual- and triple-target benchmarks demonstrate that PolyTamGen improves joint success rates over representative baselines while maintaining high chemical validity and diversity.
AVAILABILITY AND IMPLEMENTATION: The code is available at https://github.com/bjzgcai/PolyTamGen. The processed data, model checkpoints, and benchmark results are available at Zenodo: https://doi.org/10.5281/zenodo.20594128.
SUPPLEMENTARY INFORMATION: Supplementary data are available at Bioinformatics online.
RESULTS: To overcome these bottlenecks, we reformulate multi-target drug design as a sequence-based generation task and introduce PolyTamGen, an end-to-end autoregressive framework. We first curate a large-scale ligand-centric bioactivity dataset from ChEMBL and BindingDB, comprising 1.6 million unique ligands and 4.9 million bioactivity entries. PolyTamGen encodes target protein sets using ESM3, compresses these high-dimensional features into compact tokens via an attention module, and feeds them into a sequence-based compound generator to produce the final multi-target ligands. We further apply Direct Preference Optimization (DPO) to improve docking-based affinity proxies and drug-likeness. Extensive experiments on dual- and triple-target benchmarks demonstrate that PolyTamGen improves joint success rates over representative baselines while maintaining high chemical validity and diversity.
AVAILABILITY AND IMPLEMENTATION: The code is available at https://github.com/bjzgcai/PolyTamGen. The processed data, model checkpoints, and benchmark results are available at Zenodo: https://doi.org/10.5281/zenodo.20594128.
SUPPLEMENTARY INFORMATION: Supplementary data are available at Bioinformatics online.